

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number
WO 2005/032537 A1

- (51) International Patent Classification⁷: **A61K 31/20**, 9/70, A61P 25/28, 43/00
- (21) International Application Number: **PCT/JP2004/014893**
- (22) International Filing Date: 1 October 2004 (01.10.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/507,952 3 October 2003 (03.10.2003) US
2004-174577 11 June 2004 (11.06.2004) JP
- (71) Applicant (for all designated States except US): **ONO PHARMACEUTICAL CO., LTD.** [JP/JP]; 1-5, Doshomachi 2-Chome, Chuo-ku, Osaka-shi, Osaka 541-8526 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **FUNAKOSHI, Yosuke** [JP/JP]; c/o Ono Pharmaceutical Co., Ltd., 1-5, Doshomachi 2-Chome, Chuo-ku, Osaka-shi, Osaka 541-8526 (JP). **MIZUSHIMA, Ken** [JP/JP]; c/o Ono Pharmaceutical Co., Ltd., 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526 (JP). **TAKAKUWA, Toshio** [JP/JP]; c/o Ono Pharmaceutical Co., Ltd., 1-1, Sakurai 3-Chome, Shimamoto-cho, Mishima-gun, Osaka 618-8585 (JP).
- (74) Agent: **OHIE, Kunihisa**; Ohie Patent Office, Selva-Ningyosho 6F, 14-6, Nihonbashi-Ningyocho 2-chome, Chuo-Ku, Tokyo 103-0013 (JP).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE DISEASES

(57) Abstract: The invention relates to a neurodegenerative disease treating agent for parenteral use, which comprises (2R)-2-propyloctanoic acid or a salt thereof. Since the neurodegenerative disease treating agent of the present invention comprising (2R)-2-propyloctanoic acid or a salt thereof, characterized in that a dosage exceeding about 100 mg per dose is parenterally administered, shows neuropathy improving effect and S-100 β increase inhibiting effect in patients with cerebral infarction, it is useful for the treatment of neurodegenerative diseases including cerebral infarction. In addition, it is also useful as a neural regeneration agent after transplantation.